Cargando…

Gafchromic film dosimetry of a new HDR [Formula: see text] brachytherapy source

High‐dose‐rate (HDR) brachytherapy is a popular modality for treating cancers of the prostate, cervix, endometrium, breast, skin, bronchus, esophagus, and head and neck as well as soft‐tissue sarcomas. Because of different source designs and licensing issues, there is a need for specific dosimetry d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoobian, Navid, Asl, Akbar Sarabi, Poorbaygi, Hosein, Javanshir, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874862/
https://www.ncbi.nlm.nih.gov/pubmed/27074483
http://dx.doi.org/10.1120/jacmp.v17i2.6005
Descripción
Sumario:High‐dose‐rate (HDR) brachytherapy is a popular modality for treating cancers of the prostate, cervix, endometrium, breast, skin, bronchus, esophagus, and head and neck as well as soft‐tissue sarcomas. Because of different source designs and licensing issues, there is a need for specific dosimetry dataset for each HDR source model. The main objective of the present work is to measure 2D relative dose distribution around a new prototype [Formula: see text] source, referred to as IRAsource‐HDR, in PMMA phantom in the framework of AAPM TG‐43 and TG‐55 recommendations for radial distances of 0.5 cm to 4 cm. Radiochromic films (RCFs) Gafchromic EBT and HD‐810 were used for measurements. The dose rate constant, Λ, of the source was determined to be [Formula: see text] , and [Formula: see text] using EBTRCF, HD‐810 RCF, and Monte Carlo (MC) simulation, respectively. The results obtained in this study are in good agreement with previously published data for HDR interstitial [Formula: see text] ‐HDR sources with a maximum discrepancy of [Formula: see text]. An acceptable agreement (within [Formula: see text]) between MC calculations and RCFs measurements showed that HD‐810 RCF dosimetry is as good as EBTRCF, within HDR brachytherapy, and justifies the use of specific data for this new source. These data could be used as a benchmark for dose calculations in the conventional brachytherapy treatment planning systems. PACS number(s): 87.56.bg